Related by context. All words. (Click for frequent words.) 87 Initiates Phase 86 Initiates Phase II 85 Completes Patient Enrollment 84 Successfully Completes Phase 83 Commence Phase 83 Completes Enrollment 83 Initiate Phase 82 Presents Positive 81 Initiates Enrollment 81 Announces Initiation 80 Initiates Clinical Trial 80 Initiates Clinical 80 Files IND 80 Phase 2b Clinical Trial 80 Meets Primary Endpoint 80 Presents Preclinical Data 79 Receives Orphan Drug Designation 79 Initiates Phase III 79 Pivotal Phase 79 Begins Dosing 79 Presents Positive Preclinical 78 Drug Candidate 78 Randomized Phase 78 Pivotal Phase III 78 Trial Evaluating 78 Enrolls First 77 Presents Preclinical 77 Initiates Phase 2b 77 Submits IND 77 Receives Milestone Payment 77 Submits NDA 77 Commences Phase III 76 Receives Approvable Letter 76 Clinical Trial Results 76 Achieves Primary Endpoint 76 FDA Clears 76 Demonstrates Positive 76 Initiates Dosing 76 Phase 2b Trial 76 Study Evaluating 76 Novel Oral 76 Demonstrates Significant 76 Second Pivotal Phase 76 Collaborators Present 76 Phase IIb Clinical Trial 76 Signs Option Agreement 76 TKB# 75 Granted Orphan Drug 75 Patient Enrollment 75 Announces FDA Clearance 75 Initiated Phase 75 Phase IIb Trial 75 dependent kinase inhibitor 75 Therapeutic Competitors Companies 75 Receives Orphan Drug 75 Initiates Clinical Trials 75 Oral Calcitonin 75 Combination REOLYSIN R 75 Present Preclinical Data 75 Dose Ranging Study 75 Receives FDA Clearance 75 Announces Positive 75 BioSante Pharmaceuticals Announces 75 Phase III Clinical Trial 75 Announce License Agreement 75 Phase III Pivotal 75 Submits Response 75 Receives Positive 75 Initiate Phase III 74 Announces Successful Completion 74 Reports Positive 74 Receives Fast Track 74 Investigational Oral 74 pralatrexate injection folate analogue 74 PRN FDA Approves 74 Confirmatory Phase 74 Spectrum Pharmaceuticals Announces 74 Phase 1b Clinical Trial 74 Files Investigational 74 MKC# MT 74 drug pipeline TAFA# 74 Has Commenced 74 Pivotal Study 74 Receives Positive Results 74 Announces Tentative Approval 74 Confirms Significant 74 Completes Initial 73 BayStreet.ca Research Alert 73 Shows Promising 73 Clinical Trial Evaluating 73 Receives Conditional 73 initiated Phase Ib 73 Drilling Completed 73 Preclinical Data 73 Completes Dosing 73 Systemic Delivery 73 Announce Initiation 73 FDA Accepts 73 Kinase Inhibitor 73 Phase IIa Clinical Trial 73 Pivotal Phase II 73 Reports Preclinical Data 73 R roscovitine CDK cyclin 73 Licenses Novel 73 Submits Biologics License Application 73 Announce Collaboration Agreement 73 Drug Fails 73 Announce Merger Agreement 73 REG1 Anticoagulation System 73 Announces Publication 73 Immunomedics Announces 73 Therapeutic Competitors companiesandmarkets.com adEgemonye 73 Randomized Phase II 73 Announces Issuance 73 Exercises Option 72 Nasdaq XTLB 72 JAK2 Inhibitor 72 Tezampanel 72 non nucleoside inhibitor 72 Phase 2a Clinical Trial 72 Teva Provides Update 72 Metastatic Melanoma 72 Files Shelf Registration Statement 72 Receives NASDAQ 72 Matrix Phase 2b 72 Announces Poster Presentations 72 First Patient Enrolled 72 Single Dose 72 FDA Approvals 72 Gets FDA Clearance 72 Parathyroid Hormone 72 Transdermal Patch 72 Joins OTCQX 72 Pooled Analysis 72 TELINTRA R 72 Updates Status 72 Hsp# Inhibitor 72 Protease Inhibitor 72 Randomized Double blind 72 Provides Update Regarding 72 Mylan Receives Approval 72 Prolongs Survival 72 FDA Okays 72 Announces Presentation 72 Crofelemer budesonide foam 72 IIROC Resume 72 Taro Receives 72 Completes Patient Enrolment 72 Pharmaceuticals Initiates 72 2 inhibitor CYT# 72 product platforms AZX# 72 XL# anticancer compounds 72 Crowflight Announces 72 Amends Agreement 71 immunosuppressive compound 71 Successfully Completes 71 Announce Commencement 71 Cites Positive 71 Anti CD# Antibody 71 NDA Submission 71 Initiate Clinical Trial 71 Anti Tumor 71 MKC# 71 Pivotal Trial 71 Inc. Nasdaq OXGN 71 Drilling Underway 71 Phase 2a Trial 71 includes TOLAMBA TM 71 VentiRx Pharmaceuticals 71 Private Placement Closed 71 Improves Survival 71 Closes Second Tranche 71 Reveals Positive 71 Xcytrin R 71 Oral Fingolimod 71 IND Application 71 Multiple Ascending Dose 71 Biopharmaceuticals AG 71 Achieves Milestone 71 Sign License Agreement 71 Amends Private Placement 71 Sinks Lower 71 Taglich Brothers Initiates Coverage 71 Completes Financing 71 Smartstox.com Spotlights 71 Closes Financing 71 AAG geldanamycin analog 71 agonistic human 71 ABLYNX 71 Inc Therapeutic Competitors 71 Custirsen 71 GVAX ® 71 Telik logo TELINTRA 71 Phase III Trial 71 Lupus Drug 71 Receive Milestone Payment 71 Submits Application 71 Therapeutic Competitors Report 71 Announces Effective Date 71 vinorelbine tartrate 71 Severe Sepsis 71 Develop Novel 71 Significantly Increases 70 Receives Conditional Approval 70 Anticancer Compound 70 Announces Dosing 70 Investigational Compound 70 Testosterone MDTS ® 70 Reacquires 70 Confirms Efficacy 70 First Patient Dosed 70 Nasdaq MNKD focuses 70 Patient Enrolment 70 Identifies Potential 70 Vascular Disrupting Agent 70 Reports Assay Results 70 Multicenter Phase 70 Vaccine Adjuvant 70 Randomized Double Blind Placebo 70 Demonstrates Potential 70 pharmacogenomic translational research 70 Receives Shareholder Approval 70 IIROC Halt 70 Testosterone MDTS R 70 Announces License Agreement 70 Drilling Resumes 70 Drilling Extends 70 Flamel Technologies Announces 70 Receives CE Marking 70 Announces Licensing Agreement 70 Results Confirm 70 Files Patent Application 70 MKC# MKC# PP 70 oral prodrug 70 Begins Shipment 70 lead Aganocide compound 70 evaluating bafetinib 70 Chronic Hepatitis C 70 Announces Cancellation 70 Agonist MABA program 70 Tyrosine Kinase Inhibitor 70 Sign Licensing Agreement 70 Sangamo BioSciences Announces 70 Patients Treated With 70 Announce Licensing Agreement 70 Clinical Study Shows 70 Hormone Refractory Prostate Cancer 70 Receives Favorable 70 Develops Novel 70 Provides Clarification 70 Monoclonal Antibody 70 Therapeutic Antibody 70 Advanced Melanoma 70 Completes Successful 70 IND Filing 70 AZX# Phase 70 Earns Milestone Payment 70 Personalized Immunotherapy 70 Randomized Double Blind 70 R MSCRAMM 70 TO AVOID PREGNANCY WHILE 70 Refractory Hodgkin Lymphoma 70 novel VDA molecule 70 Antibody Drug Conjugate 70 Announces Commencement 70 Mg Usa 70 Initiates Drilling 70 Closes Previously Announced 70 VIVUS Announces 70 Successfully Completed 70 Shows Statistically Significant 70 Adjunctive Therapy 70 Orally Active 70 Humanized Anti 70 Phase Ib Clinical Trial 70 Magnesium Hydroxide 70 Adjuvant Treatment 70 Announces Non Brokered 70 Demonstrates Potent 70 FY# Loss Widens 70 Dose Ranging 70 By JENNIFER LEARN 70 Prospective Randomized 70 Pafuramidine 70 FDA APPROVES 69 Veronate R 69 Provides Shareholder 69 HCV Protease Inhibitor 69 Arranges Private Placement 69 FOLOTYN ® 69 Strengthens Balance Sheet 69 lexidronam injection 69 JAK Inhibitor 69 vapreotide acetate 69 Topline Results 69 telomerase therapeutic 69 Phase 2b Study 69 selective A2A adenosine receptor 69 Demonstrated Significant 69 platform HDL Mimetic 69 Lung Cancer Drug 69 Milestone Payment From 69 Preclinical Study 69 Increases Ownership 69 Clarifies Status 69 Awarded Qualifying Therapeutic 69 Shows Promise Against 69 TM Aganocide 69 Oral Insulin Capsule 69 RNAi Therapeutic 69 Treatment Naïve 69 CONTINUES LOWER 69 Obtains Approval 69 Announces Granting 69 topical gel formulation 69 Signs License Agreement 69 Acquires Exclusive 69 SPL# Gel vaginal microbicide 69 Previously Treated 69 Resumes Drilling 69 Novel Antibiotic 69 Regains NASDAQ 69 Completes Drilling 69 Dose Escalation 69 Commences Trading 69 II Clinical Trial 69 Corp. Joins OTCQX 69 Board Authorizes 69 orally administered inhibitor 69 NMT Medical Announces 69 OTCQX QRXPY 69 TSX Delisting Review 69 oral nucleoside analogue 69 Announces Termination 69 Engages CHF Investor Relations 69 Study Showed 69 VEGFR2 inhibitor 69 Secures Additional 69 Biogen Genentech 69 Concludes Acquisition 69 First Patient Treated 69 Patients Enrolled 69 novel orally inhaled 69 Prodrug 69 Receives Complete Response 69 Grants Options 69 Announces Favorable 69 Expand Collaboration 69 Further Validates 69 Small Molecule 69 TRANSDUR ™ 69 TRANSDUR ® 69 Submits Investigational 69 AllPennyStocks.com Spotlights 69 Interferon Gamma 69 Announce Completion 69 Antitumor Activity 69 Enters Option Agreement 69 Dose Finding 69 Receives Regulatory 69 Sapacitabine 69 developing Bicifadine serotonin 69 Submits Supplemental 69 Efficacy Results 69 KSP inhibitor 69 Private Placement Oversubscribed 69 Subsidiary Enters 69 Shareholders Approve Acquisition 69 Begins Clinical Trial 69 Fast Track Status 69 Jumps Higher 69 Study Demonstrates 69 Recombinant Human 69 initiated confirmatory Phase 69 Secures Financing 69 Nasdaq EPCT 69 ABL inhibitor 69 including eniluracil ADH 69 Preclinical Models 69 Commences Drill Program 69 Investigational Treatment 69 Completes Previously Announced 69 Gout Drug 69 Inks MOU 69 Ondansetron Orally Disintegrating Tablets 68 Introduces Novel 68 Shows Promise 68 Announces Proposed Acquisition 68 Key Milestones 68 FDA Approves 68 markets Testim ® 68 NOTE POSIDUR ™ 68 Amigal TM 68 CD# CEA 68 Oral Insulin 68 Successful Completion 68 Enters Into Definitive 68 Recommences 68 Vitrasert R 68 Targets Identified 68 Antigen Specific 68 pan histone deacetylase 68 Announces Signing 68 Milestone Payment 68 Successfully Concludes 68 Nasdaq VNDA 68 Announces Completion 68 Obtains Exclusive License 68 Pivotal Clinical Trial 68 Bradmer Pharmaceuticals 68 Abstract Accepted 68 Brentuximab Vedotin SGN 68 Bosutinib 68 Launches Generic Version 68 Nicotine Vaccine 68 Anti Tumor Activity 68 Receives Clearance 68 Proc Am Soc 68 Patent Covering 68 controlled multicenter Phase 68 Vicriviroc 68 4SC AG ISIN DE# 68 Significantly Improves 68 Nuvelo Announces 68 Significantly Reduces 68 Issued Patent 68 Pivotal Trials 68 ARRY # 68 Multicenter Randomized 68 Inc. OTCBB ECTE 68 novel emulsion formulation 68 Phase #b/#a clinical 68 Diabetic Foot Ulcer 68 CYP#A# CYP#D# 68 Begins Drilling 68 Improves Outcomes 68 Announces Postponement 68 Ceflatonin R 68 Announcement acc 68 Pharma Merck Serono 68 Safinamide 68 Collaborators Publish 68 ALN HPN 68 markets HP Acthar 68 rusalatide acetate 68 Phase III Clinical Trials 68 Lenocta TM 68 Announces Successful 68 Vascular Inflammation 68 selectin antagonist 68 Demonstrates Sustained 68 armodafinil Tablets C 68 please visit http:/www.vandapharma.com 68 essential thrombocythemia ET 68 BIOTECHNOLOGY SOURCE 68 Receives Patent 68 Bayer HealthCare Onyx Pharmaceuticals 68 PHASE III 68 MBRX 68 product candidate Lpathomab 68 Extends Collaboration 68 Successfully Tests 68 Pharmacokinetic Study 68 developing ACAPODENE 68 Patent Issued 68 Attenuates 68 Xeloda ® 68 LES EXPLOSIFS NORDEX LTEE 68 Mineralization Extended 68 PPD Declares 68 Closes Private Placement 68 Curr Opin 68 IG HCR ;) CO 68 successfully commercialize Iluvien 68 Provides Updates 68 ATRA IV 68 Receptor Antagonist 68 6 sulfatase 68 Identifies Significant 68 Randomized Clinical Trials 68 Updates Shareholders 68 PEGylated Fab fragment 68 Announces Brokered Private 68 Disease Modifying 68 Diabetic Neuropathy 68 Completes Second Tranche 68 Plus Ribavirin 68 Double Blind Placebo 68 Q3 Loss Widens 68 Surfactant Technology 68 #-# Full Text 68 Controlled Trial 68 Novel Compound 68 NASDAQ MNKD focuses 68 Receives Positive Opinion 68 THERAPEUTICS 68 Rated Speculative Buy 68 Plaque Psoriasis 68 Drill Hole Results 68 Gastar Exploration Announces 68 oncolytic virus therapies 68 Drug Shows Promise 68 Reduces Risk 68 Drilling Commences 68 Cynapsus Therapeutics Inc. 68 HDAC Inhibitor 68 sarcoma melanoma 68 Q1 Loss Narrows 68 Announce Receipt 68 Announces Resumption 68 Aztreonam Lysine 68 Announces Stockholder Approval 68 mGluR2 positive 68 albiglutide 68 Anticancer Agent 68 Commences Drilling Program 68 Prostate Cancer Vaccine 67 Complicated Skin 67 includes Dideco CarboMedics 67 Pharmacyclics Announces 67 anti botulism antibody 67 Staphylococcus aureus Immune Globulin 67 Mutually Agree 67 Sagent Pharmaceuticals Announces 67 Completes Private Placement 67 Achieves Positive 67 signal detection CTSD 67 Rheumatoid Arthritis Drug 67 Initiate Phase II 67 STEALTH C 67 About Chemokine Therapeutics 67 SAR# [002] 67 Successfully Completes Tender Offer 67 Elagolix 67 Announces Divestiture 67 Morgan J. Poliquin 67 Hydrochlorothiazide Tablets 67 Hana Mining Announces 67 Q2 Loss Narrows 67 Receives SFDA Approval 67 cake Mah Karn 67 Receives Tentative Approval 67 WRX STi +# mins 67 Signs Merger Agreement 67 Ecallantide 67 products MKC# PP 67 arsenic trioxide injection 67 markets XIFAXAN ® 67 Am J Obstet 67 Migraine Drug 67 Clin Oncol 67 markets COLAZAL 67 CYT# potent vascular disrupting 67 Significantly Expands 67 Telaprevir VX 67 Perifosine KRX 67 Near Surface 67 XPEL Announces 67 Jointly Announce 67 Aloprim TM allopurinol sodium 67 Liposomal 67 lead molecular radiotherapeutic 67 THE RUN DOWN 67 2 methoxyestradiol 67 Hematology Molecular Pathology 67 Announces Assay Results 67 Receives Approvals 67 Investigational Drug 67 oral picoplatin 67 TSX TVI OTCQX 67 Crit Rev 67 Announces Shareholder Approval 67 Inc. TSX ETG 67 Diamyd Medical Diamyd 67 mertansine 67 Demonstrates Ability 67 familial amyloidotic polyneuropathy FAP 67 Pruvel TM 67 delivers fluocinolone acetonide FA 67 Provides Operational Update 67 Empatic ™ 67 Completes Merger With 67 topical antifungal product 67 AnaSpec Introduces 67 Anticancer Drug 67 Shareholders Approve Arrangement 67 Commence Trading 67 BY GUILLERMO 67 Nasdaq HALO 67 Orthop Surg 67 Molecular Diagnostic Test 67 LymphoStat B belimumab 67 Commences Drilling 67 Novel Antibody 67 Announces Debt Settlement 67 SIX RO ROG 67 MCSP respectively 67 mGluR5 negative 67 Closes Acquisition 67 OTC BB PVCT 67 Drilling Intersects 67 evaluating mipomersen 67 liposomal formulation 67 Announces Filing 67 PHARMACEUTICALS INC 67 Medullary Thyroid Cancer 67 R lenalidomide 67 Generic Version 67 Metformin HCl 67 Exherin 67 Randomized Clinical Trial 67 MAG Silver Reports 67 CANALASKA URANIUM LTD 67 Releases Second Quarter 67 Q3 Loss Narrows 67 Aeolus Pharmaceuticals Announces 67 ASE SVA 67 Desvenlafaxine Succinate 67 Aflibercept 67 Subsidiary Completes 67 approved incretin mimetic 67 Placebo Controlled Trial 67 Glufosfamide 67 particularly SANCTURA XR 67 hypoxia activated prodrug 67 Ozarelix 67 Telik Announces 67 Reports Receipt 67 Obtains License 67 Barclay Hambrook P. Eng 67 GTC NASDAQ GTCB 67 candidates Azedra TM 67 AVI BioPharma Announces 67 Provides Update 67 Closes Private Placements 67 Receives Favorable Ruling 67 BY DOUGLAS HANKS 67 HCV RNA polymerase 67 Shows Efficacy 67 Announces Private Placement 67 Breakthroughstocks.net EXPLOSIVE news 67 TRACON Pharmaceuticals 67 Novel Inhibitor 67 monoclonal antibody conjugated 67 Phase Ib II 67 Starts Drilling 67 ENABLE Phase 2 67 acetonide FA 67 Enters Into Definitive Agreement 67 Trastuzumab DM1 67 Closes Flow Through 67 Pyridorin TM 67 ACCLAIM COPD 67 Demonstrates Statistically Significant 67 Secondary Hyperparathyroidism 67 Receptor Agonist 67 #/#/# DIAGNOS inc 67 J Clin 67 Testosterone Gel 67 DOR BioPharma Announces 67 Placebo Controlled 67 Obtains FDA 67 novel histone deacetylase 67 therefore therapeutically equivalent 67 CysDisplay R 67 adecatumumab MT# 67 By Denes Husty 67 Gets Bearish Confirmation 67 Therapeutic Competitors 67 lintuzumab SGN 67 5q MDS 67 Adopts Shareholder Rights 67 DP VPA 67 Gentamicin Surgical Implant 67 Omacetaxine 67 QG1 67 Alvine Pharmaceuticals 67 Genentech Wyeth Pharmaceuticals 67 oral proteasome inhibitor 67 Completes Reverse Merger 67 Completes Expansion 67 Peginterferon Alfa 2a 67 Tesetaxel 67 TSX CTI 67 Antiviral Activity 67 Announces Immediate Availability 67 Milestone Payments 67 f k Trend 67 HGS ETR1 mapatumumab 67 PHARMACEUTICALS INC. 67 NRGN 67 Mln Common 67 NASDAQ MIPI 67 Enters Into License Agreement 67 EXECUTIVE SUMMARY II 67 Phase III Trials 67 Versus Placebo 67 Q2 Loss Widens 67 Awarded Patent 67 Receives Unsolicited 67 registrational Phase 67 fentanyl citrate C 67 Randomized Phase III 67 Is Well Tolerated 66 modified glutathione analog 66 Mg Uk 66 KRYSTEXXA TM pegloticase 66 Closes Non Brokered 66 sodium glucose cotransporter 66 virus HCV protease inhibitor 66 DARA logo 66 INSPIRE Trial Phase III 66 experimental immunotherapeutics antivirals AmpligeGI mucosa resulting 66 Increases Size 66 oral ghrelin agonist 66 Eur Arch 66 Osisko Releases 66 Nasdaq PARD 66 Transgenomic Pharmacogenomics Services 66 CTAP# Injection 66 PALIS PGAL SHOW 66 STERIS Corporation Announces 66 Ondansetron Injection USP 66 Commences Production 66 Bepreve TM 66 Inc. ProMetic www.prometic.com 66 Alfacell proprietary ribonuclease 66 Expands Mineralization 66 Commences Exploration 66 COLAZAL R 66 Pharmacokinetics PK 66 Welcomes Analyst Initiation 66 NYSE Amex YMI 66 IIa Clinical Trial 66 initiated Phase 1b 66 Attracting Bullish Investors 66 recurrent metastatic ovarian cancer 66 Nasdaq MNKD focused 66 Sirolimus Eluting Stent 66 Bullish Technical Alert 66 PROCTOCORT R 66 benzoic acid hyoscyamine sulfate 66 Million Milestone Payment 66 Orally administered 66 Diabetic Nephropathy 66 Changes Ticker Symbol 66 Luramist TM 66 novel antimitotic agent 66 Seliciclib CYC# 66 Arno Therapeutics 66 Successfully Tested 66 II TRISENOX R 66 Polymerase Inhibitor 66 Sign Definitive Merger 66 occlusion PAO 66 Namenda Memantine HCl 66 TRIOLEX ™ 66 J Allergy Clin 66 SPRYCEL ® 66 TVIPF 66 Nephrol 66 Endocrinol 66 Romidepsin 66 % pramoxine HCl 66 world safest multivalent 66 Controlled Study 66 Nicotine Conjugate Vaccine 66 Proven Effective 66 Vaccine Adjuvants 66 Completes Non Brokered 66 Restructures Operations 66 Closes Oversubscribed 66 please visit http:/www.atherogenics.com 66 Announces Reverse Split 66 vesicular monoamine transporter 66 Inhibits 66 Finalizes Purchase 66 Drilling Confirms 66 dedicated CHAT ROOM 66 TM Drug Eluting 66 Frozen Shoulder syndrome Adhesive 66 Rigel R# 66 Voluntarily Withdraw 66 Efficacy Trial 66 cladribine Cladribine Tablets 66 Vitro Activity 66 Announces Dismissal 66 Closes Merger 66 Announces Operational Update 66 Salix Pharmaceuticals Announces 66 Executes Agreement 66 Commercializes 66 Files NI #-# 66 Lanthanum Carbonate 66 Terminates Agreement 66 Treatment Experienced 66 Retains CCG Investor Relations 66 Alnylam Nasdaq ALNY 66 AKT inhibitor 66 Bullish Average Crossover 66 Medoro Resources Announces 66 peptidic compound 66 oral Hsp# inhibitor 66 Q4 Loss Widens 66 IMPDH inhibitor 66 Capsulitis 66 OTCBB PYTO 66 FY# Loss Narrows 66 Finalizes Acquisition 66 AFREZZA ™ 66 Merck OSI Pharmaceuticals 66 multicenter Phase III 66 Commence Drilling 66 Regains Compliance With 66 Sign Definitive Agreement 66 Vascular Grafts 66 Patient Accrual 66 Irw Press 66 OTCBB FCSC 66 sapropterin dihydrochloride Phase 66 Files Voluntary 66 generation Hsp# inhibitor 66 Equity Funds Declare 66 Inter Citic Releases 66 Announces Adjournment 66 investigational humanized monoclonal antibody 66 Patient Treated 66 Grants Incentive 66 Evoclin R 66 Stent Restenosis 66 Announce Early Termination 66 allosteric modulator NAM 66 Consummates 66 TSX PEZ OTCBB 66 Commences Initial 66 Ovitrelle R Serostim 66 Receives Confirmation 66 Moving Average Crossover Alert 66 TSX GIX FRANKFURT GF6 66 Genentech sanofi aventis 66 :/ finance.yahoo.com q 66 By JAMAAL ABDUL 66 Releases Third Quarter 66 targeted radiotherapeutic 66 Intravitreal 66 Receives Permit 66 COMPLETES ACQUISITION OF 66 Levoleucovorin 66 Confirms Continuity 66 MIVI III 66 COMUNICADO DE 66 Closes Sale 66 PROVENGE ® 66 humanized interleukin 6 66 combines bupropion 66 TriCo Bancshares Announces 66 Phase Ib clinical trials 66 Marcus Gronholm BP 66 Angiotensin Converting Enzyme 66 Resubmission 66 Accelerate Commercialization 66 Biomarker Study 66 BIOLASE Announces 66 trastuzumab DM1 T DM1 66 Inc. NASDAQ VSGN 66 Delineates 66 Arthritis Drug 66 Adjuvant Chemotherapy 66 Poniard Pharmaceuticals Announces 66 AFREZZA TM 66 novel MetAP 2 66 Registration Statement Declared Effective 66 Files Preliminary Prospectus 66 INDUSTRY ASSESSMENTS 66 Kaydon Corporation Announces 66 Eluting Stent 66 Randomized Study 66 LifeVantage Announces 66 Cloretazine ® 66 arsenic trioxide injection GABITRIL 66 dasatinib Sprycel ® 66 beta 1a 66 OR PROPERTY DAMAGE 66 PENNY STOCK ON 66 Hypertensive Patients 66 Terminate Merger Agreement 66 Successfully Closes 66 selective phosphodiesterase 66 PI3K/Akt pathway inhibitor 66 Psoriasis Drug 66 evaluating picoplatin 66 Janus kinase 66 Review Initiated 66 Increases Private Placement 66 CORTOSS R 66 Ophthalmol 66 Vidaza R 66 Flagship Product 66 Amend Merger Agreement 66 Commences Drilling Operations 66 Income Funds Declare 66 Combination Treatment 66 Warrants Exercised 66 lead compound Traficet 66 candidates Azedra 66 Cypher Sirolimus 66 PNP inhibitor 66 compound INCB# 66 PROSTASCINT R 66 AN# topical anti 66 Patents Covering 66 RANK Ligand inhibitor 66 Backs FY# Outlook 66 Histone Deacetylase 66 Dramatically Increases 66 Soft Tissue Sarcoma 66 class anticancer quinolone 66 J Am Coll 66 Relapsing Multiple Sclerosis 66 Nasdaq PGNX 66 Osteoporosis Drug 66 L.P. Announces 66 Syncria R 66 Completes Recapitalization 66 Achieves SAS 66 Mouse Model 66 Japanese Encephalitis Vaccine 66 Benign Prostatic Hyperplasia 66 pentadentate logo R 66 Acquire Controlling Interest 66 Nat Clin Pract 66 Catalyst Biosciences 66 molecular imaging radiopharmaceutical 66 highly purified pasteurized 66 5 fluorouracil leucovorin 66 REUTERS Claro Cortes 66 Child Adolesc Psychiatry 66 TSX PTQ OTCBB PTQMF 66 Announces Normal Course 66 cefdinir PLEXION R 66 ELADUR TM 66 Int J Obes Relat 66 FOLFOX6 chemotherapy regimen 66 Postmenopausal Osteoporosis 66 Underwritten Public 66 Vantex Completes 66 visit http:/www.mannkindcorp.com 66 PANVAC VF 66 Expands Scope 66 Q4 Loss Narrows 66 Skymark Research Initiates Independent 66 Supplemental Biologics License Application 66 Projected Release Date 66 Revises FY# Outlook 66 GVAX R 66 bevacizumab Avastin R 66 ENL recurrence 65 Shai Novik President 65 Bifunctional Muscarinic Antagonist Beta2 65 Announces Underwriters Exercise 65 Drug Eluting Stent System 65 Positive Scoping Study 65 Wafer polifeprosan 65 RNAi Therapeutics 65 Enters Into Collaboration 65 Acute Attacks 65 Xian Lu 65 huC# DM4 65 NASDAQ ENMD 65 Exploration Drilling 65 GATTEX TM 65 Luveris R Ovidrel R 65 Pacific Rubiales Announces 65 neuronal nicotinic receptor NNR 65 Contrave# 65 Investigational Agent 65 hyaluronidase enzyme 65 KAI Pharmaceuticals 65 leading oral taxane 65 fibrosis IPF 65 CCR5 mAb 65 Well Tolerated 65 Commercialize Novel 65 Patients Treated 65 please visit http:/www.supergen.com 65 AUDIO PROVIDED BY 65 Surface Sampling 65 Declares Dividend Quick Facts 65 Regains Full 65 J Am Soc 65 Genotyping Test 65 Begin Clinical Trials 65 Becomes Effective 65 Inc. LATEST NEWS 65 DepoCyt ® Abelcet ® 65 monoclonal antibody IgG1 Mab 65 Qutenza TM 65 ThermoDox ® clinical 65 PFIZER INC NYSE PFE